Candidiasis; An Infection Caused By An Overgrowth Of A Type Of Yeast That Lives On The Body

Candidiasis
Candidiasis

Candidiasis is a fungal infection caused by a yeast (a type of fungus) called Candida. Some species of Candida can cause infection in people; most common is Candida albicans. These fungi normally live on and in the body. They live harmlessly, but can cause a variety of health problems, including yeast infections and invasive Candida.

The common term for Candida in the vagina is vaginal yeast infection. (vaginitis). Most women have infection at some point in their lives. The condition typically resolves on its own, but in some it may not go away without treatment.

The size of the world's Candidiasis Market was estimated at US$ 873.8 million in 2017 and is anticipated to grow at a CAGR of 4.6% over the next five years (2018–2026).

A vaginal yeast infection is caused by an overgrowth of fungus called candida. An infection causes the skin around a vagina to burn and itch, and it may change the consistency of vaginal discharge. A vaginal yeast infection affects around 75% of people at least once in their lifetime.

Although rare, serious cases of invasive Candidiasis affect around 25,000 individuals in the U.S. each year. Candida albicans is the most common type of fungus to cause yeast infections. Candida fungus can be more difficult to treat, and generally need more-aggressive therapies.

Candida is in the mouth, throat, or esophagus is usually treated with antifungal medication, such as clotrimazole, miconazole, or nystatin. For mild to moderate infections in the mouth or throat, an antifungal medicine is applied to the inside of the mouth for 7 to 14 days.

Antimycotic medicines are another name for Antifungal Drugs or therapies. It is a pharmaceutical fungicide or fungistatic used to treat and prevent major systemic infections as well as mycosis such as athlete's foot, ringworm, and candidiasis (thrush).

For adults, the initial recommended antifungal treatment is echinocandin (caspofungin, micafungin, or anidulafungin) given through a vein (intravenous or IV). Fluconazole, amphotericin B, and other antifungal drugs may also be appropriate in certain situations.

While symptoms of Candidiasis cause discomfort, treatment with an antifungal medication is very successful in eliminating the infection. In 2022, the U.S. Food and Drug Administration (USFDA) approved Osteseconazole (Vivjoa), an azole antifungal agent for the prevention of recurrent yeast infections in females who are not of reproductive potential.

Comments

Post a Comment

Popular posts from this blog

Sarcopenia Treatment; Training and Physical Exercise Is Key to Counteract Sarcopenia

Image
Sarcopenia Treatment A primary Sarcopenia Treatment is exercise. Researchers have identified resistance training as the specific form of exercise that is most beneficial to individuals with sarcopenia. At present, resistance exercise, protein supplementation, and vitamin D have been established as the basic treatment of sarcopenia. Recent clinical trials on sarcopenia therapies such as physical exercise, nutraceutical, and pharmaceutical interventions have revealed that exercise is the only effective strategy shown to alleviate sarcopenia. Sarcopenia refers to a loss of muscle mass specifically related to aging. It's normal to lose some muscle mass as people age. Sarcopenia has been defined as an age-related, involuntary loss of skeletal muscle mass and strength. Although aging is the main cause of sarcopenia, some other factors contribute to the loss of muscle mass. Getting little or no physical activity on a regular basis puts people at an increased risk of developing sarcopenia
Read more

Bioresorbable Implants Can Also Help To Prevent Complications And Speed Up The Recovery Process

Image
Bioresorbable Implants Medical implants, either passive for structural support or for diagnosis and therapy with active electronics, are widely used in surgical applications. Although they have shown long-term biocompatibility, their removal imposes physical, biological and economical burdens on patients. To overcome this drawback, implantable devices exhibiting biodegradation in the body have been developed. These implants disappear inside the body after a certain time of use, and can be replaced with natural bone. The resorption of Bioresorbable Implants is driven by hydrolysis of the bonds linking their monomers. The amorphous portions of the polymer degrade first, while the crystalline regions remain intact and provide most of their mechanical strength. The monomers are then broken down into lactic and glycolic acids, which are converted to pyruvate and then processed through the citric acid cycle into water and carbon dioxide. The Bioresorbable Implants Market was valued at US$
Read more

Increasing Developments by Key Players Are Expected To Augment the Growth of the Global Digital Pathology Market

Image
 Digital Pathology Digital Pathology Market , by Product Type (Image Analysis Software, Scanner {Bright Field Scanner, Fluorescence Scanner}, Services {Installation & Integration, Maintenance Services, Consulting Services}), by Therapeutic Area (Oncology, Hematology, Autoimmune Disorder, Dermatology, and Others), by Technology (Immunohistochemistry, ISH & FISH, Immunofluorescence and others) End User (Pharmaceutical & Biotechnology Companies, Diagnostic Labs, Hospital Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030. The global Digital Pathology Market is anticipated to reach an estimated value of US$ 884.4 million in 2023 and is projected to grow at a CAGR of 12.2% from 2023 to 2030. Market Overview: Digital pathology refers to the practice of digitizing glass slides containing tissue samples and analyzing them using digital imaging technology
Read more